Morgan Stanley Reiterates “$46.00” Price Target for Catalent (CTLT)

Morgan Stanley set a $46.00 price objective on Catalent (NYSE:CTLT) in a research report report published on Monday morning. The brokerage currently has a buy rating on the stock.

CTLT has been the topic of several other reports. Zacks Investment Research lowered Catalent from a hold rating to a sell rating in a research report on Monday, September 3rd. Royal Bank of Canada set a $45.00 price objective on Catalent and gave the company a buy rating in a research report on Friday, November 16th. First Analysis raised Catalent from a neutral rating to an outperform rating and cut their price objective for the company from $47.00 to $43.00 in a research report on Wednesday, November 7th. ValuEngine raised Catalent from a hold rating to a buy rating in a research report on Monday, November 12th. Finally, UBS Group initiated coverage on Catalent in a research report on Tuesday, October 9th. They issued a neutral rating and a $48.00 price objective on the stock. One analyst has rated the stock with a sell rating, two have given a hold rating and ten have given a buy rating to the stock. The stock has a consensus rating of Buy and an average target price of $48.00.

Shares of CTLT opened at $37.31 on Monday. The company has a debt-to-equity ratio of 1.44, a quick ratio of 1.61 and a current ratio of 2.05. The firm has a market capitalization of $5.53 billion, a P/E ratio of 23.47, a PEG ratio of 2.38 and a beta of 1.44. Catalent has a twelve month low of $34.24 and a twelve month high of $47.87.

Catalent (NYSE:CTLT) last issued its earnings results on Tuesday, November 6th. The company reported $0.28 earnings per share for the quarter, topping the consensus estimate of $0.24 by $0.04. The business had revenue of $551.80 million for the quarter, compared to analyst estimates of $582.44 million. Catalent had a return on equity of 19.13% and a net margin of 2.65%. The business’s quarterly revenue was up 1.5% on a year-over-year basis. During the same period last year, the company posted $0.21 EPS. Equities research analysts expect that Catalent will post 1.63 EPS for the current year.

In other news, SVP Lance Miyamoto sold 6,525 shares of Catalent stock in a transaction dated Tuesday, October 16th. The stock was sold at an average price of $42.50, for a total transaction of $277,312.50. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Donald E. Morel, Jr. bought 10,000 shares of the company’s stock in a transaction dated Thursday, September 13th. The shares were acquired at an average cost of $43.00 per share, for a total transaction of $430,000.00. The disclosure for this purchase can be found here. Over the last ninety days, insiders have sold 184,335 shares of company stock worth $8,161,727. Corporate insiders own 1.40% of the company’s stock.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Seven Eight Capital LP acquired a new position in Catalent in the third quarter worth about $506,000. Commonwealth of Pennsylvania Public School Empls Retrmt SYS acquired a new position in Catalent in the second quarter worth about $1,508,000. Millennium Management LLC grew its stake in Catalent by 4,244.2% in the second quarter. Millennium Management LLC now owns 1,200,267 shares of the company’s stock worth $50,279,000 after purchasing an additional 1,172,638 shares in the last quarter. Aperio Group LLC grew its stake in Catalent by 7.0% in the third quarter. Aperio Group LLC now owns 33,563 shares of the company’s stock worth $1,529,000 after purchasing an additional 2,185 shares in the last quarter. Finally, Tibra Equities Europe Ltd acquired a new position in Catalent in the second quarter worth about $6,653,000. 96.77% of the stock is currently owned by institutional investors and hedge funds.

Catalent Company Profile

Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel Technologies, Biologics and Specialty Drug Delivery, Oral Drug Delivery, and Clinical Supply Services. The Softgel Technologies segment formulates, develops, and manufactures prescription and consumer soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.

See Also: Cash Flow

Analyst Recommendations for Catalent (NYSE:CTLT)

Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply